CH
BLACR

CVI Holdings’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

CVI Holdings’s Portfolio BLACR Stock Details BLACR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$15.6K Hold
156,176
– – 0.01% 78
2024
Q1 		$23.4K Hold
156,176
– – 0.02% 61
2023
Q4 		$23.4K Hold
156,176
– – 0.05% 60
2023
Q3 		$43.7K Buy
+156,176
New +$30.8K 0.09% 61

Other funds holding BLACR

HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

CVI Holdings's BLACR Position: Q2 2024 in Review

CVI Holdings held its Bellevue Life Sciences Acquisition Corp. Rights (BLACR) position steady in Q2 2024 at 156,176 shares worth $15.6K. The position accounts for 0.01% of the portfolio, ranked #78.

CVI Holdings first reported a position in BLACR in Q3 2023 and has held it in 4 quarters since. The position peaked at $43.7K in Q3 2023. 30 funds tracked by Wall St. Rank hold BLACR as of Q2 2024.

  • CVI Holdings held 156,176 shares of Bellevue Life Sciences Acquisition Corp. Rights worth $15.6K as of Q2 2024.
  • CVI Holdings left its Bellevue Life Sciences Acquisition Corp. Rights share count unchanged in Q2 2024.
  • Bellevue Life Sciences Acquisition Corp. Rights made up 0.01% of CVI Holdings's portfolio in Q2 2024, its #78 holding.
  • CVI Holdings first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q3 2023 and has held it in 4 quarters since.
  • CVI Holdings's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $43.7K in Q3 2023.
  • 30 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q2 2024.

Based on CVI Holdings's 13F filing for Q2 2024, filed 15 Aug 2024.